
Medline Sales Surge 10.7% to $7.4 Billion Despite Tariff and IPO Cost Headwinds
Medline Inc.Description
What this story covers
Medline reported robust Q1 2026 revenue growth of 10.7%, reaching $7.4 billion. While tariffs and IPO-related expenses pressured GAAP net income, the company raised its full-year sales guidance, signaling strong demand and a resilient balance sheet.
Story snapshot
CompanyMedline Inc.
TickerMDLN
VariantStandard detailed
Duration6:09
Filing type8-K
PeriodQ1 2026
IndustryHealthcare & Pharmaceuticals
Accession0002046386-26-000022
Sources1
Full Story Script
Content not available for this story.